Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Korro Bio, Inc. (KRRO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on Nasdaq. Korro focuses on RNA-editing genetic medicines, and its filings with the U.S. Securities and Exchange Commission offer detailed information on clinical programs, collaborations, restructuring actions, and executive changes that complement its press releases.
Investors can review Forms 10-K and 10-Q for narrative and financial discussion of Korro’s development of KRRO-110 for Alpha-1 Antitrypsin Deficiency, the REWRITE Phase 1/2a clinical trial design, and the OPERA RNA editing platform. These periodic reports also describe risk factors, research and development spending, and collaboration revenue, including from its research collaboration and license agreement with Novo Nordisk A/S.
Current reports on Form 8-K are particularly relevant for tracking material events at Korro. Recent 8-K filings describe the amendment to the Novo Nordisk collaboration establishing a 12‑month pause in research and development activities, strategic restructuring and workforce reductions intended to extend cash runway, and executive transitions such as the resignation of the Chief Financial Officer and Chief Medical Officer and related separation agreements. Other 8-Ks outline compensatory arrangements, including amended employment agreements and equity awards.
Users can also monitor proxy statements and compensation disclosures referenced in Korro’s 8-Ks for background on executive employment terms, as well as any Form 4 insider transaction reports that may be filed to reflect equity grants or option exercises under the company’s stock plans. Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, highlight important sections of long reports, and help readers quickly understand how new filings may relate to Korro’s RNA-editing pipeline, collaborations, and capital allocation.
Korro Bio, Inc. Schedule 13G/A shows Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 1,538,296 shares of Common Stock, representing 10.7% of 14,422,571 shares outstanding as of March 11, 2026. The disclosed position reflects shared voting and shared dispositive power over those shares.
Lynx1 Master Fund LP, an entity associated with Lynx1 Capital Management LP and Weston Nichols, reported an indirect open-market purchase of 520 shares of Korro Bio, Inc. common stock at $10.60 per share. Following this transaction, the reporting structure shows 1,538,296 shares held indirectly. Lynx1 Capital Management LP and Mr. Nichols each disclaim beneficial ownership except to the extent of any pecuniary interest.
Korro Bio, Inc. reported an initial insider ownership filing showing that investment entities associated with Lynx1 Capital Management LP and Weston Nichols indirectly hold 1,537,776 shares of common stock. The shares are held by Lynx1 Master Fund LP, and both the investment manager and Mr. Nichols disclaim beneficial ownership except for any pecuniary interest.
Korro Bio Inc — The Vanguard Group filed an amendment to a Schedule 13G/A stating it beneficially owns 0 shares of Korro Bio common stock, representing 0% of the class. The filing explains that, on January 12, 2026, The Vanguard Group underwent an internal realignment and certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538.
Korro Bio, Inc. is registering for resale up to 7,650,764 shares of common stock, consisting of 4,501,928 shares of common stock and 3,148,836 shares issuable upon exercise of pre-funded warrants, pursuant to registration rights from a March 9, 2026 private placement. The resale registration covers shares held by the identified selling stockholders and does not mean they will sell all or any of their shares. The company will not receive proceeds from sales by the selling stockholders, though it will receive the nominal exercise price for any exercised pre-funded warrants.
Korro Bio, Inc. reports a Schedule 13G disclosing a group filing by Venrock-related entities and principals regarding beneficial ownership. The Reporting Persons state aggregated holdings tied to pre-funded warrants and common stock that are capped by a "Beneficial Ownership Blocker" preventing exercise above 9.99%.
The filing cites 14,422,571 shares of common stock outstanding as of March 10, 2026 and notes the group is currently capped at beneficial ownership of 1,488,685 shares, representing 9.99% of the class (EDGAR rounding shows 9.9% on cover pages). The group’s positions include stated pre-funded warrants exercisable into additional shares; exercise is restricted to avoid exceeding the ownership blocker.
Korro Bio filed a shelf registration to permit resale of up to 7,650,764 shares of common stock by selling stockholders. The amount comprises 4,501,928 issued common shares and 3,148,836 shares issuable upon exercise of pre-funded warrants under a March 9, 2026 private placement.
The resale is a secondary offering by the selling stockholders; the company states it will not receive proceeds from those resales (other than the $0.001 per-share exercise price if pre-funded warrants are exercised for cash). Percentage ownership in the prospectus is based on 14,422,571 shares outstanding as of March 11, 2026.
Korro Bio, Inc. reported that investment entities associated with Rick Yang made significant indirect open-market purchases of its securities. On March 10, 2026, New Enterprise Associates 17, L.P. acquired 242,945 Pre-Funded Warrants at $11.1090 per warrant and 207,100 shares of Common Stock at $11.1100 per share under a Subscription Agreement dated March 9, 2026. Following these transactions, NEA 17 indirectly holds 1,297,893 shares of Common Stock and the Pre-Funded Warrants, while the Reporting Person disclaims beneficial ownership where there is no pecuniary interest. The Pre-Funded Warrants are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ prior notice.
SANDELL SCOTT D reported open-market purchase transactions in this Form 4 filing.
Korro Bio, Inc. insider entities linked to Scott D. Sandell indirectly acquired 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock on March 10, 2026, pursuant to a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants carry a $0.001 exercise price and are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ notice.